Dallas hospital defends treatment of Ebola patient

| | Health Exec | Precision Medicine

One day following the death of Thomas Eric Duncan, the first person to die of Ebola in the U.S., Texas Health Presbyterian Hospital formally responded to criticisms about his care, according to Huffington Post.

"Our team provided Mr. Duncan with the same high level of attention and care that would be given any patient, regardless of nationality or ability to pay for care," according to a hospital statement. "We have a long history of treating a multicultural community in this area."

Read more below:

Dallas Hospital Responds To Criticisms of Ebola Patient's Treatment

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.